Koike Ai, Arimura-Omori Masako, Umeda Shuyo, Takano Akihisa, Kishikawa Yasuyuki, Nakamura Satoshi, Takahata Yuriko, Okamatsu Yuki, Fujita Akitaka, Harada Taishi
Department of Respiratory Medicine, Japan Community Health Care Organization Kyushu Hospital, Fukuoka, Japan.
Department of Surgery, Japan Community Health Care Organization Kyushu Hospital, Fukuoka, Japan.
Respir Med Case Rep. 2023 Nov 27;46:101950. doi: 10.1016/j.rmcr.2023.101950. eCollection 2023.
We present a case of a 45-year-old woman diagnosed with interstitial pneumonia (IP) during a comprehensive breast cancer evaluation. Although the patient showed no obvious clinical symptoms of polymyositis or dermatomyositis, the presence of anti-glycyl-transfer ribonucleic acid synthetase antibodies confirmed anti-synthetase syndrome. The patient began methylprednisolone for treatment of the IP. She then received preoperative chemotherapy with epirubicin and cyclophosphamide before undergoing a mastectomy. A significant improvement was seen in the patient's IP during treatment. This case emphasizes the potential advantages of personalized immunosuppressive therapy for patients who are simultaneously diagnosed with anti-synthetase syndrome and cancer.
我们报告了一例45岁女性病例，该患者在全面的乳腺癌评估过程中被诊断出患有间质性肺炎（IP）。尽管患者未表现出多发性肌炎或皮肌炎的明显临床症状，但抗甘氨酰转移核糖核酸合成酶抗体的存在确诊了抗合成酶综合征。患者开始使用甲泼尼龙治疗IP。随后，她在接受乳房切除术之前接受了表柔比星和环磷酰胺的术前化疗。治疗期间患者的IP有显著改善。该病例强调了对同时诊断为抗合成酶综合征和癌症的患者进行个性化免疫抑制治疗的潜在优势。
